Plasma NT-proBNP as predictor of change in functional status, cardiovascular morbidity and mortality in the oldest old: The Leiden 85-plus study

Age

Volumn 36, Issue 3, 2014, Pages 1541-1554

  Van Peet, Petra G ^a   De Craen, Anton J M ^a   Gussekloo, Jacobijn ^a   De Ruijter, Wouter ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Activities of daily living; Aged 80 years and over; Cardiovascular disease; Cardiovascular morbidity; Cardiovascular mortality; Cognition; Prediction; Prevention; Pro brain natriuretic peptide

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADL DISABILITY; AGED; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; FUNCTIONAL DISEASE; FUNCTIONAL STATUS; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POPULATION RESEARCH; PREDICTION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; REVIEW; VERY ELDERLY; AGING; BLOOD; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDY; DAILY LIFE ACTIVITY; GERIATRIC ASSESSMENT; MORBIDITY; NETHERLANDS; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; TRENDS;

ACTIVITIES OF DAILY LIVING; AGED, 80 AND OVER; AGING; BIOMARKERS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; GERIATRIC ASSESSMENT; HUMANS; INCIDENCE; MALE; MORBIDITY; NATRIURETIC PEPTIDE, BRAIN; NETHERLANDS; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE;

EID: 84905394619     PISSN: 01619152     EISSN: 15744647     Source Type: Journal    
DOI: 10.1007/s11357-014-9660-1     Document Type: Review

References (57)

1. Alehagen U, Goetze JP, Dahlstr{combining double acute accent}m U (2007) Reference intervals and decision limits for B-type natriuretic peptide (BNP) and its precursor (NT-proBNP) in the elderly. Clinica Chimica Acta 382:8-14 (Pubitemid 46782725)
2. Beleigoli AM, Ribeiro AL, Diniz MdF, Lima-Costa MF, Boersma E (2013a) Comparing the value of BNP in predicting mortality among community-dwelling elderly with and without overweight/obesity: the Bambuï (Brazil) Cohort Study of Aging. Int J Cardiol 168(4):4364-4366
3. Beleigoli AM, Boersma E, Diniz MF, Vidigal PG, Lima-Costa MF, Ribeiro AL (2013b) C-reactive protein and B-type natriuretic peptide yield either a non-significant or a modest incremental value to traditional risk factors in predicting long-term overall mortality in older adults. PLoSOne 8:e75809
4. Campbell DJ (2008) Can measurement of B-type natriuretic peptide levels improve cardiovascular disease prevention? Clin Exp Pharmacol Physiol 35:442-446
5. Cantril H (1965) The pattern of human concerns. Rutgers University Press, New Brunswick (NJ)
6. Daniels LB, Laughlin GA, Kritz-Silverstein D, Clopton P, Chen WC,Maisel AS, Barrett-Connor E (2011) Elevated natriuretic peptide levels and cognitive function in community-dwelling older adults. AmJ Med 124:670-678
7. de Craen AJ, Heeren TJ, Gussekloo J (2003) Accuracy of the 15-item geriatric depression scale (GDS-15) in a community sample of the oldest old. Int J Geriatr Psychiatry 18:63-66 (Pubitemid 36131228)
8. de Ruijter W, Westendorp RG, Assendelft WJ, den Elzen WP, de Craen AJ, le Cessie S, Gussekloo J (2009) Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. BMJ 338:a3083
9. DeFilippi C, van Kimmenade RR, Pinto YM (2008) Amino-terminal pro-B-type natriuretic peptide testing in renal disease. Am J Cardiol 101:82-88
10. Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, Thompson A, Gudnason V, Sattar N, Danesh J (2009) B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 120:2177-2187
11. Eggers KM, Venge P, Lind L (2013) Prognostic usefulness of the change in N-terminal pro B-type natriuretic peptide levels to predict mortality in a single community cohort aged >/=70 years. Am J Cardiol 111:131-136
12. Feinkohl I, Sattar N, Welsh P, Reynolds RM, Deary IJ, Strachan MW, Price JF (2012) Association of N-terminal pro-brain natriuretic peptide with cognitive function and depression in elderly people with type 2 diabetes. PLoSOne 7:e44569
13. Garcia BH, Smabrekke L, Trovik T, Giverhaug T (2013) Application of the MAT-CHDSP to assess guideline adherence and therapy goal achievement in secondary prevention of coronary heart disease after percutaneous coronary intervention. EurJ ClinPharmacol 69:703-709
14. Groenning BA, Raymond I, Hildebrandt PR, Nilsson JC, Baumann M, Pedersen F (2004) Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 90:297-303 (Pubitemid 38250725)
15. Hiltunen M, Kerola T, Kettunen R, Hartikainen S, Sulkava R, Vuolteenaho O, Nieminen T (2013) The prognostic capacity of B-type natriuretic peptide on cognitive disorder varies by age. Ann Med 45:74-78
16. Kalantarian S, Stern TA,Mansour M, Ruskin JN (2013) Cognitive impairment associated with atrial fibrillation: a meta-analysis. Ann Intern Med 158:338-346
17. Kavousi M, Elias-Smale S, Rutten JH, Leening MJ, Vliegenthart R, Verwoert GC, Krestin GP, Oudkerk M, de Maat MP, Leebeek FW, Mattace-Raso FU, Lindemans J, Hofman A, Steyerberg EW, van der Lugt A, van den Meiracker AH, Witteman JC (2012) Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med 156:438-444
18. Kerola T, Nieminen T, Hartikainen S, Sulkava R, Vuolteenaho O, Kettunen R (2010) B-type natriuretic peptide as a predictor of declining cognitive function and dementia-a cohort study of an elderly general population with a 5-year follow-up. Ann Med 42:207-215
19. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P (2005) N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA: J Am Med Assoc 293:1609-1616 (Pubitemid 40471791)
20. Koopman C, Vaartjes I, Heintjes EM, Spiering W, van Dis I, Herings RM, Bots ML (2013) Persisting gender differences and attenuating age differences in cardiovascular drug use for prevention and treatment of coronary heart disease, 1998-2010. Eur.Heart J
21. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC Jr, Hoffman E, Goto S, Ohman EM, Bhatt DL (2013) Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis. AmJ Med 126:693-700
22. Laslett LJ, Alagona P Jr, Clark BA III, Drozda JP Jr, Saldivar F, Wilson SR, Poe C, Hart M (2012) The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J Am Coll Cardiol 60:S1-S49
23. Linssen GC, Bakker SJ, Voors AA, Gansevoort RT, Hillege HL, de Jong PE, van Veldhuisen DJ, Gans RO, de Zeeuw D (2010) N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. EurHeart J 31:120-127
24. Longstreth WT Jr, Kronmal RA, Thompson JL, Christenson RH, Levine SR, Gross R, Brey RL, Buchsbaum R, Elkind MS, Tirschwell DL, Seliger SL, Mohr JP, deFilippi CR (2013) Amino terminal pro-B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy. Stroke
25. Macfarlane PW, Latif S (1996) Automated serial ECG comparison based on the Minnesota code. J Electrocardiol 29(Suppl):29-34 (Pubitemid 27051630)
26. Maisel AS, Daniels LB (2012) Breathing not properly 10 years later: what we have learned and what we still need to Learn. J Am Coll Cardiol 60:277-282
27. Marz W, Tiran B, Seelhorst U, Wellnitz B, Bauersachs J, Winkelmann BR, Boehm BO (2007) N-terminal pro-B-type natriuretic peptide predicts total and cardiovascular mortality in individuals with or without stable coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health Study. Clin Chem 53:1075-1083 (Pubitemid 46867524)
28. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engstrom G, Persson M, Smith JG, Magnusson M, Christensson A, Struck J, Morgenthaler NG, Bergmann A, Pencina MJ, Wang TJ (2009) Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA: J Am Med Assoc 302:49-57
29. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD et al (2012) Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2197-2223
30. Nadir MA, Rekhraj S, Wei L, Lim TK, Davidson J, MacDonald TM, Lang CC, Dow E, Struthers AD (2012) Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart disease. J Am Coll Cardiol 60:960-968
31. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Ibsen H, Torp-Pedersen C, Hildebrandt PR (2007) N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J 28:1374-1381 (Pubitemid 47355969)
32. Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS, Kronmal RA (2009) N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. Circulation 120:1768-1774
33. Pencina MJ, d'Agostino RB, Vasan RS (2010) Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med 48:1703-1711
34. Pencina MJ, D'Agostino RB Sr, Steyerberg EW (2011) Extensions of net reclassification improvement calculations to measure usefulness of newbiomarkers. StatMed 30:11-21
35. Perreault S, Yu AY, Cote R, Dragomir A, White-Guay B, Dumas S (2012) Adherence to antihypertensive agents after ischemic stroke and risk of cardiovascular outcomes. Neurology 79:2037-2043
36. Pikula A, Beiser AS, Decarli C, Himali JJ, Debette S, Au R, Selhub J, Toffler GH, Wang TJ, Meigs JB, Kelly-Hayes M, Kase CS, Wolf PA, Vasan RS, Seshadri S (2012) Multiple biomarkers and risk of clinical and subclinical vascular brain injury: the framingham offspring study. Circulation 125:2100-2107
37. Rienstra M, McManus DD, Benjamin EJ (2012) Novel risk factors for atrial fibrillation: useful for risk prediction and clinical decision making? Circulation 125:e941-e946
38. Rutten FH, Hoes AW (2008) B-type natriuretic peptide assays for detecting heart failure in the elderly: same value as those in the younger? Int J Cardiol 125:161-165 (Pubitemid 351400228)
39. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutlerand D, Auerbach AD (2004) A note on competing risks in survival data analysis. Br J Cancer 91(7):1229-1235 (Pubitemid 39424779)
40. Schnabel RB, Aspelund T, Li G, Sullivan LM, Suchy-Dicey A, Harris TB, Pencina MJ, D'Agostino RB Sr, Levy D, Kannel WB, Wang TJ, Kronmal RA, Wolf PA, Burke GL, Launer LJ, Vasan RS, Psaty BM, Benjamin EJ, Gudnason V, Heckbert SR (2010) Validation of an atrial fibrillation risk algorithm in whites and African Americans. Arch Intern Med 170:1909-1917
41. Suwa M, Ito T (2009) Correlation between cognitive impairment and left ventricular diastolic dysfunction in patients with cardiovascular diseases. Int J Cardiol 136:351-354
42. Tombaugh TN, McIntyre NJ (1992) The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 40:922-935
43. Ueda R, Yokouchi M, Suzuki T, Otomo E, Katagiri T (2003) Prognostic value of high plasma brain natriuretic peptide concentrations in very elderly persons. Am J Med 114:266-270 (Pubitemid 36398070)
44. Uthoff H, Staub D, Socrates T, Meyerhans A, Bundi B, Schmid HP, Frauchiger B (2010) PROCAM-, FRAMINGHAM-, S. Vasa 39:325-333
45. Vaes B, de Ruijter W, Degryse J, Westendorp RG, Gussekloo J (2009a) Clinical relevance of a raised plasma N-terminal probrain natriuretic peptide level in a population-based cohort of nonagenarians. J Am Geriatr Soc 57:823-829
46. Vaes B, de Ruijter W, Gussekloo J, Degryse J (2009b) The accuracy of plasma natriuretic peptide levels for diagnosis of cardiac dysfunction and chronic heart failure in community-dwelling elderly: a systematic review. Age Ageing 38:655-662
47. Valle R, Aspromonte N, Barro S, Canali C, Carbonieri E, Ceci V, Chinellato M, Gallo G, Giovinazzo P, Ricci R, Milani L (2005) The NT-proBNP assay identifies very elderly nursing home residents suffering from pre-clinical heart failure. Eur J Heart Fail 7:542-551 (Pubitemid 40732985)
48. van Peet PG, Drewes YM, de Craen AJ, Gussekloo J, de Ruijter W (2013a) NT-proBNP best predictor of cardiovascular events and cardiovascular mortality in secondary prevention in very old age: the Leiden 85-plus Study. PLoSOne 8:e81400
49. van Peet PG, Drewes YM, de Craen AJ, Westendorp RG, Gussekloo J, de Ruijter W (2013b) Prognostic value of cardiovascular disease status: the Leiden 85-plus study. Age (Dordr) 35:1433-1444
50. Verduijn M, Grootendorst DC, Dekker FW, Jager KJ, le Cessie S (2011) The analysis of competing events like cause-specific mortality-beware of the Kaplan-Meier method. Nephrol Dial Transplant 26:56-61
51. Wallen T, Landahl S, Hedner T, Nakao K, Saito Y (1997) Brain natriuretic peptide predicts mortality in the elderly. Heart 77:264-267 (Pubitemid 27122781)
52. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. NEnglJMed 350:655-663 (Pubitemid 38364624)
53. Wang TJ, Gona P, LarsonMG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, d'Agostino B, Vasan RS (2006) Multiple biomarkers for the prediction of first major cardiovascular events and death. NEnglJMed 355:2631-2639 (Pubitemid 44969122)
54. Wannamethee SG, Welsh P, Lowe GD, Gudnason V, Di AE, Lennon L, Rumley A, Whincup PH, Sattar N (2011) Nterminal pro-brain natriuretic Peptide is a more useful predictor of cardiovascular disease risk than C-reactive protein in older men with and without pre-existing cardiovascular disease. J Am Coll Cardiol 58:56-64
55. Weber M, Hamm C (2006) Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 92:843-849 (Pubitemid 43799232)
56. Welsh P, Doolin O, Willeit P, Packard C, Macfarlane P, Cobbe S, Gudnason V, Di Angelantonio E, Ford I, Sattar N (2013) N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS. Eur. Heart J 34:443-450
57. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, Venge P, Arnlov J (2008) Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. NEnglJMed 358:2107-2116 (Pubitemid 351679597)